Laura Okpala
Executive Director & Head of Reimbursement Policy & Government Affairs Gilead Sciences
At Gilead Sciences, Ms. Okpala leads the US reimbursement policy team focused on driving access to innovative medicines across Gilead’s oncology and virology portfolio, including reimbursement strategies for Kite Pharma, a leader in the development of novel CAR T therapies.
Seminars
Wednesday 15th July 2026
Fireside Chat: Shaping the Future of Cell & Gene Therapy Access
9:00 am
- Examining how evolving clinical data, payer expectations and policy shifts are redefining commercial success for advanced therapies
- Understanding how affordability pressures, evidence requirements and real-world delivery constraints are shaping near term and long-term market viability
- Exploring what manufacturers, payers and providers need to prioritize to sustain patient access as pipelines expand into larger and more common indications
Thursday 16th July 2026
Advancing Sustainable Payment Strategies for Cell & Gene Therapies
3:30 pm
- Creating flexible payment structures that reduce upfront burden and support broader patient access
- Applying payment approaches to align reimbursement with outcomes and essential procedural steps
- Leveraging Medicaid to carve out policies to secure additional rebates and maintain access in financially constrained environments
